^
Association details:
| Biomarker: | PD-L1 amplification |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
099 | 9p gain predicts outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with R-GemOx +/- Atezolizumab. ARGO: A randomised phase II study
Published date:
06/09/2021
Excerpt:
In Arm B A 840mg IV was added every 14 days from cycle 2 onwards, responding pts continued with A at 840mg every 21 days for 8 cycles....In Arm B, ORR, PFS and OS were higher in tumours with gain of PD-L1 locus at 9p by FISH (10/29), median PFS 7.2 months 9p gain vs 3.2 months normal P = 0.037…
Secondary therapy:
R-GemOx
